Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Claudia MaletzkiLeonie WiegeleIngy NassarJan StenzelChristian JunghanssPublished in: Journal for immunotherapy of cancer (2019)
Combined chemo-immunotherapy impairs tumor onset and growth likely attributable to modulation of immune responses. Depleting or 're-educating' immunosuppressive cell types, such as MDSC, may help moving a step closer to combat cancer.